Pharmaceuticals & Biotechnology
Valuation | |
|---|---|
| Market Cap | 13.85 kCr |
| Price/Earnings (Trailing) | 25.38 |
| Price/Sales (Trailing) | 2.71 |
| EV/EBITDA | 13.48 |
| Price/Free Cashflow | 46.92 |
| MarketCap/EBT | 19.23 |
| Enterprise Value | 14.88 kCr |
Fundamentals | |
|---|---|
Growth & Returns | |
|---|---|
| Price Change 1W | 1% |
| Price Change 1M | -4.7% |
| Price Change 6M | 26.3% |
| Price Change 1Y | 1.1% |
| 3Y Cumulative Return | 24.5% |
| 5Y Cumulative Return | 11.1% |
| 7Y Cumulative Return | 30.4% |
| 10Y Cumulative Return | 17.4% |
| Revenue (TTM) |
| 5.11 kCr |
| Rev. Growth (Yr) | 21.1% |
| Earnings (TTM) | 545.48 Cr |
| Earnings Growth (Yr) | 27.7% |
Profitability | |
|---|---|
| Operating Margin | 14% |
| EBT Margin | 14% |
| Return on Equity | 13.7% |
| Return on Assets | 7.86% |
| Free Cashflow Yield | 2.13% |
Cash Flow & Liquidity |
|---|
| Cash Flow from Investing (TTM) | -691.29 Cr |
| Cash Flow from Operations (TTM) | 866.57 Cr |
| Cash Flow from Financing (TTM) | -92.51 Cr |
| Cash & Equivalents | 608.61 Cr |
| Free Cash Flow (TTM) | 294.87 Cr |
| Free Cash Flow/Share (TTM) | 12.15 |
Balance Sheet | |
|---|---|
| Total Assets | 6.94 kCr |
| Total Liabilities | 2.96 kCr |
| Shareholder Equity | 3.98 kCr |
| Current Assets | 3.09 kCr |
| Current Liabilities | 2.42 kCr |
| Net PPE | 2.61 kCr |
| Inventory | 1.49 kCr |
| Goodwill | 11.65 Cr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.24 |
| Debt/Equity | 0.41 |
| Interest Coverage | 5.82 |
| Interest/Cashflow Ops | 9.67 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 1.5 |
| Dividend Yield | 0.26% |
| Shares Dilution (1Y) | 0.10% |
| Shares Dilution (3Y) | 0.30% |
Balance Sheet: Strong Balance Sheet.
Profitability: Recent profitability of 11% is a good sign.
Size: Market Cap wise it is among the top 20% companies of india.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Past Returns: Outperforming stock! In past three years, the stock has provided 24.5% return compared to 12.8% by NIFTY 50.
Momentum: Stock has a weak negative price momentum.
Technicals: SharesGuru indicator is Bearish.
Smart Money: Smart money is losing interest in the stock.
Insider Trading: Significant insider selling noticed recently.
Balance Sheet: Strong Balance Sheet.
Profitability: Recent profitability of 11% is a good sign.
Size: Market Cap wise it is among the top 20% companies of india.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Past Returns: Outperforming stock! In past three years, the stock has provided 24.5% return compared to 12.8% by NIFTY 50.
Momentum: Stock has a weak negative price momentum.
Technicals: SharesGuru indicator is Bearish.
Smart Money: Smart money is losing interest in the stock.
Insider Trading: Significant insider selling noticed recently.
Investor Care | |
|---|---|
| Dividend Yield | 0.26% |
| Dividend/Share (TTM) | 1.5 |
| Shares Dilution (1Y) | 0.10% |
| Earnings/Share (TTM) | 22.48 |
Financial Health | |
|---|---|
| Current Ratio | 1.28 |
| Debt/Equity | 0.41 |
Technical Indicators | |
|---|---|
| RSI (14d) | 39.07 |
| RSI (5d) | 49.26 |
| RSI (21d) | 43.54 |
| MACD Signal | Sell |
| Stochastic Oscillator Signal | Hold |
| SharesGuru Signal | Sell |
| RSI Signal | Hold |
| RSI5 Signal | Hold |
| RSI21 Signal | Hold |
| SMA 5 Signal | Sell |
| SMA 10 Signal |
Summary of Granules India's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Understand Granules India ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| KRISHNA PRASAD CHIGURUPATI | 31.65% |
| CHIGURUPATI UMA DEVI | 3.81% |
| SBI LIFE INSURANCE CO. LTD | 3.34% |
| ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED A/C | 2.05% |
| KOTAK MAHINDRA LIFE INSURANCE COMPANY LTD. | 1.74% |
| TYCHE INVESTMENTS PRIVATE LIMITED | 1.46% |
| BASAVA SANKARA RAO KOLLI |
Detailed comparison of Granules India against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries | 3.83 LCr | 58.94 kCr | -7.20% | -8.30% | 36.59 | 6.72 | - | - |
| DIVISLAB | Divi's Lab | 1.61 LCr |
Comprehensive comparison against sector averages
GRANULES metrics compared to Pharmaceuticals
| Category | GRANULES | Pharmaceuticals |
|---|---|---|
| PE | 25.38 | 33.27 |
| PS | 2.71 | 4.61 |
| Growth | 14.2 % | 8.6 % |
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationlly. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; high potent products; and other products for oncology. Granules India Limited was founded in 1984 and is based in Hyderabad, India.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
| Buy |
| SMA 20 Signal | Sell |
| SMA 50 Signal | Sell |
| SMA 100 Signal | Sell |
GRANULES vs Pharmaceuticals (2021 - 2026)
| 1.2% |
| TATA MUTUAL FUND - TATA AGGRESSIVE HYBRID FUND | 1.11% |
| PRAGNYA CHIGURUPATI | 0.76% |
| CHIGURUPATI PRIYANKA | 0.75% |
| SANTHI SREE RAMANAVARAPU | 0.35% |
| SUSEELA DEVI CHIGURUPATI | 0.03% |
| NIKHILA REDDY YEDAGURI | 0.01% |
| HARSHA CHIGURUPATI | 0% |
| KALIDINDI ABINAV VARMA | 0% |
| VENKATA MAHESH KRISHNA NARRA | 0% |
Distribution across major stakeholders
Distribution across major institutional holders
| 10.46 kCr |
| -5.30% |
| +5.50% |
| 64.65 |
| 15.36 |
| - |
| - |
| CIPLA | Cipla | 1.07 LCr | 29.37 kCr | -12.40% | - | 23.52 | 3.64 | - | - |
| DRREDDY | Dr. Reddy's Lab | 1.02 LCr | 36.09 kCr | -4.20% | +2.00% | 18.22 | 2.82 | - | - |
| AUROPHARMA | Aurobindo Pharma | 70.14 kCr | 33.03 kCr | +2.10% | +2.10% | 20.49 | 2.12 | - | - |
| 14.9% |
| 202 |
| 176 |
| 170 |
| 167 |
| 153 |
| 128 |
| Exceptional items before tax | - | 0 | 0 | -25.91 | 31 | 0 | 0 |
| Total profit before tax | 14.9% | 202 | 176 | 145 | 198 | 153 | 128 |
| Current tax | 44% | 73 | 51 | 38 | 62 | 37 | 31 |
| Deferred tax | -232.5% | -20.88 | -5.58 | -6.24 | -16.26 | -1.75 | -0.13 |
| Total tax | 15.9% | 52 | 45 | 32 | 46 | 35 | 31 |
| Total profit (loss) for period | 14.6% | 150 | 131 | 113 | 152 | 118 | 97 |
| Other comp. income net of taxes | -52.6% | 19 | 39 | 19 | 11 | 10 | 3.71 |
| Total Comprehensive Income | -0.6% | 169 | 170 | 132 | 163 | 128 | 101 |
| Earnings Per Share, Basic | 18.5% | 6.19 | 5.38 | 4.64 | 6.27 | 4.85 | 4.01 |
| Earnings Per Share, Diluted | 18.5% | 6.19 | 5.38 | 4.64 | 6.27 | 4.85 | 4.01 |
| -12.7% |
| 63 |
| 72 |
| 39 |
| 16 |
| 24 |
| 27 |
| Depreciation and Amortization | 1.4% | 146 | 144 | 146 | 126 | 118 | 102 |
| Other expenses | 11% | 739 | 666 | 601 | 553 | 446 | 401 |
| Total Expenses | -15.7% | 2,674 | 3,170 | 3,277 | 2,736 | 2,416 | 1,944 |
| Profit Before exceptional items and Tax | -33.1% | 396 | 591 | 664 | 520 | 733 | 392 |
| Exceptional items before tax | - | 31 | 0 | 0 | 0 | 0 | 161 |
| Total profit before tax | -27.8% | 427 | 591 | 664 | 520 | 733 | 553 |
| Current tax | -27.3% | 110 | 151 | 170 | 134 | 197 | 122 |
| Deferred tax | -179.3% | -1.99 | 4.77 | -5.05 | -0.38 | -16.97 | -13.27 |
| Total tax | -30.5% | 108 | 155 | 165 | 133 | 180 | 109 |
| Total profit (loss) for period | -26.9% | 319 | 436 | 499 | 387 | 553 | 444 |
| Other comp. income net of taxes | -58.5% | 4.08 | 8.43 | -4.69 | 14 | -5.51 | -27.05 |
| Total Comprehensive Income | -27.3% | 323 | 444 | 494 | 400 | 547 | 417 |
| Earnings Per Share, Basic | -28.4% | 13.17 | 18 | 20.32 | 15.6 | 22.18 | 17.47 |
| Earnings Per Share, Diluted | -28.4% | 13.17 | 17.99 | 20.3 | 15.55 | 22.09 | 17.41 |
| 20.7% |
| 1,547 |
| 1,282 |
| 987 |
| 941 |
| 818 |
| 677 |
| Loans, non-current | - | 0 | 0 | 0 | 0 | 6.04 | 12 |
| Total non-current financial assets | 20.3% | 1,563 | 1,299 | 1,003 | 957 | 840 | 713 |
| Total non-current assets | 11.1% | 3,184 | 2,865 | 2,444 | 2,372 | 2,277 | 2,185 |
| Total assets | 5.6% | 5,443 | 5,152 | 4,658 | 5,006 | 4,853 | 4,503 |
| Borrowings, non-current | - | 0 | 0 | 0 | 50 | 98 | 149 |
| Total non-current financial liabilities | 1.2% | 87 | 86 | 5.23 | 57 | 106 | 157 |
| Provisions, non-current | -3.2% | 31 | 32 | 44 | 38 | 33 | 29 |
| Total non-current liabilities | -3.4% | 143 | 148 | 83 | 126 | 170 | 210 |
| Borrowings, current | 14.1% | 922 | 808 | 727 | 1,004 | 1,054 | 762 |
| Total current financial liabilities | 8.8% | 1,681 | 1,545 | 1,335 | 1,728 | 1,780 | 1,561 |
| Provisions, current | 16.7% | 36 | 31 | 12 | 12 | 11 | 15 |
| Current tax liabilities | 109.1% | 24 | 12 | 6.01 | 4.22 | 9.01 | 9.01 |
| Total current liabilities | 9.5% | 1,752 | 1,600 | 1,363 | 1,769 | 1,814 | 1,594 |
| Total liabilities | 8.3% | 1,894 | 1,749 | 1,447 | 1,895 | 1,984 | 1,804 |
| Equity share capital | 0% | 24 | 24 | 24 | 24 | 24 | 24 |
| Total equity | 4.3% | 3,549 | 3,403 | 3,211 | 3,111 | 2,869 | 2,699 |
| Total equity and liabilities | 5.6% | 5,443 | 5,152 | 4,658 | 5,006 | 4,853 | 4,503 |
| -42.3% |
| 91 |
| 157 |
| 177 |
| 143 |
| - |
| - |
| Net Cashflows From Operating Activities | 160.1% | 823 | 317 | 664 | 280 | - | - |
| Cashflows used in obtaining control of subsidiaries | 59.9% | 340 | 213 | 0 | 0 | - | - |
| Proceeds from sales of PPE | -233.3% | 0 | 1.75 | 0.2 | 0.98 | - | - |
| Purchase of property, plant and equipment | 76.5% | 211 | 120 | 212 | 325 | - | - |
| Proceeds from sales of investment property | - | 6.22 | 0 | 0 | 0 | - | - |
| Interest received | -33.5% | 2.11 | 2.67 | 3.84 | 12 | - | - |
| Other inflows (outflows) of cash | -142.9% | -9.72 | 26 | 111 | -6.42 | - | - |
| Net Cashflows From Investing Activities | -82.1% | -552.43 | -302.98 | -96.45 | -318.45 | - | - |
| Proceeds from issuing shares | 85.2% | 5 | 3.16 | 2.78 | 3.21 | - | - |
| Payments to acquire or redeem entity's shares | - | 0 | 0 | 311 | 0 | - | - |
| Proceeds from borrowings | 7.5% | 2,099 | 1,952 | 0 | 303 | - | - |
| Repayments of borrowings | 28.9% | 2,341 | 1,816 | 149 | 95 | - | - |
| Payments of lease liabilities | 104.5% | 9.14 | 4.98 | 0 | 4.72 | - | - |
| Dividends paid | 0% | 36 | 36 | 19 | 37 | - | - |
| Interest paid | -21.1% | 57 | 72 | 37 | 17 | - | - |
| Net Cashflows from Financing Activities | -1463.3% | -339.82 | 26 | -519.47 | 151 | - | - |
| Effect of exchange rate on cash eq. | -1012.5% | -1.19 | 1.24 | -0.25 | 0.94 | - | - |
| Net change in cash and cash eq. | -279.3% | -70.74 | 41 | 48 | 114 | - | - |